Literature DB >> 6989546

Disposition of captopril in normal subjects.

K J Kripalani, D N McKinstry, S M Singhvi, D A Willard, R A Vukovich, B H Migdalof.   

Abstract

The disposition of captopril, an angiotensin-converting enzyme inhibitor with antihypertensive properties, was studied in 10 normal male subjects after a single 100-mg tablet of 35S-labeled drug. Average absorption parameters for unchanged captopril in blood were Tmax 0.93 +/- 0.08 hr and Cmax 800 +/- 76 ng/ml. For total radioactivity in blood the values were Tmax 1.05 +/- 0.08 hr and Cmax 1,580 +/- 90 ng/ml (as captopril equivalents). Because of the curvilinearity of the semilogarithmic plots of blood concentrations of captopril:time, elimination half-life (t1/2) of unchanged drug could not be determined. At 1 hr unchanged captopril accounted for about 52% of total radioactivity in blood, and the dimeric disulfide metabolite of captopril accounted for about 10%. In the first 5 days after dosing, an average of about 68% of the radioactive dose was recovered in urine and 18% in feces. The distribution of radioactivity in the first 24-hr urine sample (66% of the dose) was 58% captopril (38% of dose), 2% captopril disulfide (1.5% of dose), and 40% unidentified polar metabolites (26% of dose).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6989546     DOI: 10.1038/clpt.1980.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  37 in total

1.  Pharmacokinetics of intravenous captopril in healthy men.

Authors:  W A Creasey; R A Morrison; S M Singhvi; D A Willard
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Estimate of volume/flow ratio of gastrointestinal (GI) fluids in humans using pharmacokinetic data.

Authors:  P Macheras; C Reppas; J B Dressman
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Angiotensin converting enzyme inhibition: a new therapeutic modality.

Authors:  H Gavras; F Charocopos; H Brunner; I Gavras
Journal:  Bull N Y Acad Med       Date:  1981-05

Review 4.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

5.  Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

Authors:  C Richer; B Giroux; P F Plouin; B Maarek; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

6.  Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs.

Authors:  Y Abe; T Okahara; K Miura; T Yukimura; T Takada; T Iwatani; T Iso; K Yamamoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

Review 7.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 8.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

9.  Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors:  E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

Review 10.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.